Zofran (ondansetron) MDL Arguments Heard October 1, 2015

October 1st was a significant day in the Zofran (ondansetron) litigation, as the Judicial Panel on Multidistrict Litigation met to consider the arguments for consolidating several lawsuits against the anti-nausea drug’s manufacturer, GlaxoSmithKline (“GSK”). The ruling will be the first big step in the litigation, as plaintiffs are vying to have their cases centralized before one judge in one court to coordinate discovery and pretrial proceedings in what is known as a multidistrict litigation, or an MDL.  GSK has filed a motion to consolidate all cases in the Eastern District of Pennsylvania, closest to its co-headquarters, while plaintiffs have sought coordination elsewhere.

Mothers whose children were born with birth defects after taking Zofran (ondansetron), namely cleft palate and congenital heart defects, are blaming GSK for marketing the drug off label to pregnant women to treat morning sickness. Approved by the FDA only to treat nausea and vomiting in patients who underwent surgery or chemotherapy, the drug was reportedly illegally marketed as safe to give to expectant mothers.  Plaintiffs’ firm Grant & Eisenhofer has been investigating and filing cases on behalf of children and families since the inception of the litigation, including one of the most recent cases filed in the Central District of California.  The case alleges that Zofran (ondansetron) caused Vanessa Birt’s son to develop cleft palate, requiring surgery to correct the defect when he was only nine months old.

If you or a loved one took Zofran (ondansetron) for morning sickness during your first trimester and your baby was born with a cleft palate or congenital heart defect, please contact us at 877-978-0169 for a confidential evaluation of your potential claim.

Real Time Analytics